TScan Therapeutics, Inc.TCRXNASDAQ

Revenue (LTM)

$10M

+266.7% YoY

Net Income (LTM)

$-130M

-1.8% YoY

Free Cash Flow

$-140M

Revenue CAGR (5Y)

+0.5%

Marginsdeclining

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	10	14↑33.5%	21↑55.5%	3↓86.6%	10↑266.7%
Gross Profit	10	14↑33.5%	21↑55.5%	3↓86.6%	7↑164.9%
Operating Income	-49	-67↓37.0%	-93↓40.3%	-135↓44.3%	-136↓0.7%
Net Income	-49	-66↓36.2%	-89↓34.7%	-127↓42.9%	-130↓1.8%
EBITDA	-45	-60↓32.3%	-80↓33.7%	-120↓49.5%	-133↓11.0%
EPS Diluted	-2.03	-2.74↓35.0%	-1.36↑50.4%	-1.14↑16.2%	-1.00↑12.3%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	161	120↓25.6%	133↑11.1%	179↑34.0%	152↓14.7%
Total Current Assets	166	124↓25.1%	194↑56.5%	293↑50.7%	152↓47.9%
Total Assets	188	199↑5.8%	272↑36.7%	371↑36.4%	229↓38.4%
Total Current Liabilities	21	17↓18.9%	30↑72.3%	36↑20.6%	19↓48.0%
Total Liabilities	27	100↑264.7%	121↑21.7%	130↑7.3%	106↓18.8%
Total Equity	161	99↓38.2%	151↑51.7%	241↑59.7%	123↓48.9%
Total Debt	6	86↑1322.9%	92↑7.5%	97↑5.4%	94↓3.3%
Net Debt	-155	-34↑78.1%	-41↓20.2%	-81↓98.7%	-58↑28.3%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-49	-67↓36.6%	-61↑7.7%	-111↓80.6%	-135↓22.1%
Capital Expenditure	-10	-4↑57.5%	-3↑25.5%	-4↓21.6%	-4↓15.2%
Free Cash Flow	-59	-71↓20.7%	-65↑8.8%	-115↓77.7%	-140↓21.9%
Stock-Based Comp	3	5↑80.9%	5↑14.4%	10↑83.4%	12↑22.6%
Net Change in Cash	131	-41↓131.6%	13↑132.2%	45↑240.2%	-26↓158.0%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance